Key Takeaways From Biogen Analyst Ratings
In the latest quarter, 19 analysts provided ratings for Biogen (NASDAQ:BIIB), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 8 | 7 | 4 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 2 | 0 | 0 | 0 |
| 2M Ago | 3 | 2 | 0 | 0 | 0 |
| 3M Ago | 4 | 2 | 4 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $285.32, a high estimate of $342.00, and a low estimate of $200.00. A decline of 2.16% from the prior average price target is evident in the current average.
Understanding Analyst Ratings: A Comprehensive Breakdown
The perception of Biogen by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Christopher Raymond | Piper Sandler | Lowers | Overweight | $313.00 | $335.00 |
| Ami Fadia | Needham | Maintains | Buy | $294.00 | $294.00 |
| Brian Abrahams | RBC Capital | Maintains | Outperform | $317.00 | $317.00 |
| Brian Abrahams | RBC Capital | Maintains | Outperform | $317.00 | $317.00 |
| Brian Abrahams | RBC Capital | Maintains | Outperform | $317.00 | $317.00 |
| Brian Abrahams | RBC Capital | Maintains | Outperform | $317.00 | - |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $300.00 | $300.00 |
| Ami Fadia | Needham | Maintains | Buy | $294.00 | $294.00 |
| Robyn Karnauskas | Truist Securities | Maintains | Buy | $340.00 | $340.00 |
| Morten Herholdt | HSBC | Raises | Buy | $342.00 | $339.00 |
| Jay Olson | Oppenheimer | Maintains | Outperform | $270.00 | $270.00 |
| Ami Fadia | Needham | Maintains | Buy | $294.00 | $294.00 |
| Carter Gould | Barclays | Lowers | Equal-Weight | $200.00 | $215.00 |
| Laura Chico | Wedbush | Raises | Neutral | $215.00 | $213.00 |
| Andrew Fein | HC Wainwright & Co. | Lowers | Buy | $300.00 | $325.00 |
| Ami Fadia | Needham | Maintains | Buy | $294.00 | $294.00 |
| Jay Olson | Oppenheimer | Lowers | Outperform | $270.00 | $290.00 |
| Colin Bristow | UBS | Lowers | Neutral | $214.00 | $250.00 |
| Laura Chico | Wedbush | Lowers | Neutral | $213.00 | $245.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Biogen. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Biogen compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Biogen's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Biogen's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Biogen analyst ratings.
Delving into Biogen's Background
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
A Deep Dive into Biogen's Financials
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: Biogen's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -7.0%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Biogen's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 17.18%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Biogen's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.62% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Biogen's ROA stands out, surpassing industry averages. With an impressive ROA of 1.47%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.46, Biogen adopts a prudent financial strategy, indicating a balanced approach to debt management.
Understanding the Relevance of Analyst Ratings
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.